EUVIMEDEUVIMED entdecken
Crossref

Depemokimab (Exdensur) for Severe Eosinophilic Asthma

The Medical Letter on Drugs and Therapeutics · 16.03.2026 · 68 (1750) · 44-46

DOI: 10.58347/tml.2026.1750b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 16.03.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved depemokimab (Exdensur – GSK), a long-acting interleukin-5 (IL-5) antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients ≥12 years old. Depemokimab is the fourth IL-5-directed treatment to be approved in the US for this indication; the IL-5 antagonists mepolizumab (Nucala) and reslizumab (Cinqair) and the IL-5 receptor alpha antagonist benralizumab (Fasenra) were approved earlier.

Schlagwörter

Stichwörter der Autor:innen

CinqairDupixentExdensurFasenraNucalaTezspireXolairadverse effectsasthmabenralizumabdepemokimabdosagedupilumabefficacyinhaled corticosteroids

Zitieren

APA

(2026). Depemokimab (Exdensur) for Severe Eosinophilic Asthma. The Medical Letter on Drugs and Therapeutics, 68(1750), 44-46. https://doi.org/10.58347/tml.2026.1750b

Vancouver

Depemokimab (Exdensur) for Severe Eosinophilic Asthma. The Medical Letter on Drugs and Therapeutics. 2026;68(1750):44-46. doi:10.58347/tml.2026.1750b

BibTeX
@article{euvimed2026,
  title = {Depemokimab (Exdensur) for Severe Eosinophilic Asthma},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1750},
  pages = {44--46},
  doi = {10.58347/tml.2026.1750b}
}
Kostenlos starten →